在药物的微封装中,以脂肪酸为基础的菌混合物作为相变材料的应用:制备,表征和释放行为
Fariba Ghaffari1, Hemayat Shekaari2
1Department of Physical Chemistry, University of Tabriz, Tabriz, Iran.
BMC chemistry
|February 18, 2025
概括
这项研究使用生物基相变材料 (PCM) 开发了微囊,以改善可溶性较差的药物如环素,巴克洛芬和生物素的输送. 微封装药物显示了增强的热稳定性和持续释放特征.
科学领域:
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
- 化学工程是化学工程的重要组成部分.
背景情况:
- 微封装是一种多功能技术,在化学,食品和制药行业具有重要应用.
- 药物输送系统从微封装中受益,特别是在提高药物稳定性和调节释放方面.
- 相变材料 (PCM) 为药物微封装提供了一种新的方法,特别是当它们的相变温度与生理条件保持一致时.
研究的目的:
- 使用生物基相变材料 (PCM) 开发和描述水溶性较差的药物 (环素,巴克洛芬,生物素) 的微囊.
- 调查PCM的适用性,其相位过渡温度接近人体温度 (310K),用于药物输送.
- 评估开发的微囊的热稳定性和药物释放概况.
主要方法:
- 选择酸-酸 (1: 3摩尔比) 的优混合物作为PCM,因为它在310K附近具有最佳的相变特性.
- 制造球形微囊,其核心外形态封装了环素,巴克洛芬和生物素.
- 使用里叶变换红外光谱 (FT-IR) 和扫描电子显微镜 (SEM) 进行了表征.
- 使用热重力测量分析 (TGA) 进行热稳定性分析.
- 使用差分扫描热量计 (DSC) 进行相位过渡分析.
- 在 310.15 K 和 318.15 K 的酸盐缓冲盐水 (PBS,pH 7.4) 中进行了体外药物释放研究.
主要成果:
- 通过FT-IR和SEM成功形成了具有核心外结构的球形微囊.
- 微封装药物在工作温度下表现出极好的热稳定性,如TGA所示.
- DSC的结果显示,微囊药物的点接近PCM的点.
- 观察到持续的药物释放,每种药物约有50%和60%在24小时内分别在310.15K和318.15K释放.
结论:
- 开发的生物基PCM微囊适用于增强水溶性较差的药物的稳定性和受控释放.
- 选择的PCM在体温附近的相位过渡特性有助于有效的药物输送.
- 这种微封装策略对先进的制药配方和药物输送系统具有前景.
相关概念视频
Micelles
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...


